Today's Trend
Avantor, Inc. (NYSE: AVTR) is trading higher as investors assess a mixed batch of Zacks Research earnings-estimate revisions. The changes suggest modestly improved longer-term earnings expectations, although several near-term forecasts were reduced.
- Zacks raised its EPS forecasts for Avantor’s fiscal 2026 to $0.80 from $0.78, fiscal 2027 to $0.85 from $0.84, and fiscal 2028 to $0.92 from $0.91. It also increased its Q2 2027 estimate to $0.22 from $0.19 and Q2 2028 to $0.23 from $0.22. The upward full-year revisions may support the stock by signaling improving earnings prospects.
- Zacks maintained a “Hold” rating on AVTR. Its fiscal 2026 estimate of $0.80 remains slightly below the broader consensus of $0.81, limiting the strength of the positive signal.
- Zacks lowered its Q4 2026 EPS estimate to $0.22 from $0.23, Q1 2027 to $0.18 from $0.19, and Q3 2027 to $0.22 from $0.23. These reductions point to some near-term earnings pressure and partially offset the longer-term upgrades.
- Recent coverage also focused on Avantor’s results and its performance relative to other medical stocks, but the supplied reports did not provide a new company announcement or additional operating catalyst. Avantor Results Put Market Expectations To Test
Overall, the stock’s positive performance appears consistent with the net improvement in full-year and longer-term EPS forecasts, though the “Hold” rating and downward near-term revisions suggest investors may remain cautious.